The application of molecular biology to neuroscience, as well as contributions from the Human Genome Project, have resulted in much progress in identifying genes and molecular mechanisms that can be targeted to treat neurological and psychiatric disorders. But addressing the complexity of the brain and its diseases is a tall order that still requires the evolution of rational therapies.

Trophix Pharmaceuticals Inc. has acquired a portfolio of genes that it hopes will lead to drug discovery for nervous disorders and help fill the dearth of available therapies.